Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and ABVD for Newly Diagnosed Hodgkin's Lymphoma
NCT00369681Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- May 2006
- Primary completion
- Oct 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in Hodgkin lymphoma (HL), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Effect of Rituximab on EBV(+) Tumors up to 56 months and Relationship Between Marker Detection and Clinical Outcome at 3 years. Started May 2006; status: completed.
02
Drugs
rituximab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00369681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00369681.